Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Mirati Therapeutics Stock Is on the Move Again Today

By Cory Renauer - Updated Oct 29, 2019 at 1:26PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This time, its own clinical trial is pushing the biotech higher.

What happened

Shares of Mirati Therapeutics (MRTX 11.12%), a clinical-stage biopharmaceutical company, are rising again today. This time, the stock is soaring in response to highly anticipated clinical trial data produced by Mirati, instead of by a similar program from Amgen (AMGN -0.30%). Investors who are relieved that Mirati's experimental cancer drug MRTX849 performed arguably better than Amgen's AMG 510 pushed the stock 15% higher as of 11:49 p.m. EDT on Tuesday.

So what 

A mutated KRAS gene was one of the first gene-specific drivers of tumor growth elucidated by researchers decades ago. Unfortunately, KRAS proteins have a relatively smooth shape that has made them impossible to inhibit, until recently.

Man in a suit looking up at an upward sloping chart.

Image source: Getty Images.

Earlier this year, Amgen presented initial results from a trial with its KRAS inhibitor, AMG 510, that impressed investors and pushed up Mirati stock in the process. Mirati's climbing again today because the company presented phase 1 results from its own KRAS inhibitor, MRTX849, and it appears competitive with Amgen's. The highest dosage tested shrank tumors for three out of five evaluable lung cancer patients and one out of two colon cancer patients.

Now what

It's really not a good idea to compare results from two different populations, but without a head-to-head study, it's all we have to work with. In September, Amgen's AMG 510 lost some of its luster after the company showed it shrank tumors for just one colon cancer patient out of 12 who received the highest dosage tested. Among 13 evaluable lung cancer patients who received the highest dosage, researchers measured tumor shrinkage in seven.

It's important to point out that studies run by Amgen and Mirati enrolled patients who hadn't responded or relapsed after several previous lines of treatment. Getting any of these patients to respond to a new therapy is a noteworthy achievement. At the moment, though, it looks like Mirati has a better candidate.

An estimated 14% of lung cancer patients and perhaps 4% of colon cancer patients have tumors driven by the KRAS mutation that MRTX849 targets. If Mirati Therapeutics can continue producing results that perform as well or better than Amgen, the company's $3.7 billion market cap at recent prices could swell to several times its size and make Mirati one of the best performing biotech stocks in the years ahead.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends Amgen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Mirati Therapeutics, Inc. Stock Quote
Mirati Therapeutics, Inc.
MRTX
$86.56 (11.12%) $8.66
Amgen Inc. Stock Quote
Amgen Inc.
AMGN
$246.25 (-0.30%) $0.73

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.